EMTRICITABINE/TENOFOVIR DISOPROXIL ZENTIVA 200 mg/245 mg, film-coated tablet 30 tablets
Active ingredients: Emtricitabine, Tenofovir disoproxil phosphate, Tenofovir disoproxil
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- EMTRICITABINE/TENOFOVIR DISOPROXIL ZENTIVA 200 mg/245 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 1 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 30 comprimé(s)
- Marketing authorisation holder
- ZENTIVA (REPUBLIQUE TCHEQUE)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 22 May 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66010949CIP73007688CIP133400930076880Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TÉNOFOVIR DISOPROXILcomprimé | 245 mg · un comprimé | FT |
| EMTRICITABINEcomprimé | 200 mg · un comprimé | SA |
| PHOSPHATE DE TÉNOFOVIR DISOPROXILcomprimé | 291,50 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.